ES2552643T3 - Pirrolopiridinas como inhibidores de cinasa - Google Patents
Pirrolopiridinas como inhibidores de cinasa Download PDFInfo
- Publication number
- ES2552643T3 ES2552643T3 ES09747404.3T ES09747404T ES2552643T3 ES 2552643 T3 ES2552643 T3 ES 2552643T3 ES 09747404 T ES09747404 T ES 09747404T ES 2552643 T3 ES2552643 T3 ES 2552643T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- phenyl
- hydrogen
- optionally substituted
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000005255 pyrrolopyridines Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 132
- -1 -SO2Ri Chemical group 0.000 abstract description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 51
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 43
- 229910052736 halogen Inorganic materials 0.000 abstract description 41
- 150000002367 halogens Chemical group 0.000 abstract description 41
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract description 40
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 29
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 29
- 239000001257 hydrogen Substances 0.000 abstract description 29
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract description 22
- 125000000217 alkyl group Chemical group 0.000 abstract description 22
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 19
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 16
- 125000004429 atom Chemical group 0.000 abstract description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract description 13
- 125000003118 aryl group Chemical group 0.000 abstract description 13
- 229920006395 saturated elastomer Polymers 0.000 abstract description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract description 2
- 125000003342 alkenyl group Chemical group 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 49
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 125000004043 oxo group Chemical group O=* 0.000 description 40
- 230000014759 maintenance of location Effects 0.000 description 21
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 14
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 12
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZEFGUWRQFNTGGX-UHFFFAOYSA-N 1,6-dihydropyridazine Chemical compound C1NN=CC=C1 ZEFGUWRQFNTGGX-UHFFFAOYSA-N 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JBSLANHIBKBQGE-UHFFFAOYSA-N 2-cyclopropylacetamide Chemical compound NC(=O)CC1CC1 JBSLANHIBKBQGE-UHFFFAOYSA-N 0.000 description 1
- OAAKFAXUEYTMHF-UHFFFAOYSA-N 2-ethoxyacetamide Chemical compound CCOCC(N)=O OAAKFAXUEYTMHF-UHFFFAOYSA-N 0.000 description 1
- DRYMMXUBDRJPDS-UHFFFAOYSA-N 2-hydroxy-2-methylpropanamide Chemical compound CC(C)(O)C(N)=O DRYMMXUBDRJPDS-UHFFFAOYSA-N 0.000 description 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 1
- WOMBHFDZBLZRLM-UHFFFAOYSA-N 2-propan-2-yloxyacetamide Chemical compound CC(C)OCC(N)=O WOMBHFDZBLZRLM-UHFFFAOYSA-N 0.000 description 1
- OYBQCUZBVHFPBU-UHFFFAOYSA-N 5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=N1 OYBQCUZBVHFPBU-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- QMZJNIBYRKNKLS-UHFFFAOYSA-N n-[4-(2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrol-5-yl)-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C12=C(N3CC4NCCC4C3)C(Br)=CN=C2NC=C1NC(=O)C1=CC=CN=C1 QMZJNIBYRKNKLS-UHFFFAOYSA-N 0.000 description 1
- PKEACBQJQHBPIJ-LLVKDONJSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-1-methylpyrazole-4-carboxamide Chemical compound C1=NN(C)C=C1C(=O)NC1=CNC2=NC=C(Br)C(N3C[C@H](N)CCC3)=C12 PKEACBQJQHBPIJ-LLVKDONJSA-N 0.000 description 1
- WCLCXCDIPAFMMJ-GFCCVEGCSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-ethylsulfanyl-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C12=C(N3C[C@H](N)CCC3)C(SCC)=CN=C2NC=C1NC(=O)C1CC1 WCLCXCDIPAFMMJ-GFCCVEGCSA-N 0.000 description 1
- CTMQPNJRLWACHG-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound C=12C(NC(=O)C(C)C)=CNC2=NC=C(F)C=1N1CCC[C@@H](N)C1 CTMQPNJRLWACHG-SNVBAGLBSA-N 0.000 description 1
- MLSFOTDQXORALM-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1[C@H](N)CCCN1C1=C(F)C=NC2=C1C(NC(=O)C1CC1)=CN2 MLSFOTDQXORALM-SNVBAGLBSA-N 0.000 description 1
- RRYDBRRFZNMWLI-SECBINFHSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl]propanamide Chemical compound C=12C(NC(=O)CC)=CNC2=NC=C(F)C=1N1CCC[C@@H](N)C1 RRYDBRRFZNMWLI-SECBINFHSA-N 0.000 description 1
- ONQBAALYRROEEE-LLVKDONJSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-methylsulfanyl-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound CSC1=CN=C2NC=C(NC(=O)C(C)C)C2=C1N1CCC[C@@H](N)C1 ONQBAALYRROEEE-LLVKDONJSA-N 0.000 description 1
- XQRRDAPJHUPNLH-GFCCVEGCSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-propan-2-yl-1h-pyrrolo[2,3-b]pyridin-3-yl]propanamide Chemical compound C=12C(NC(=O)CC)=CNC2=NC=C(C(C)C)C=1N1CCC[C@@H](N)C1 XQRRDAPJHUPNLH-GFCCVEGCSA-N 0.000 description 1
- HHWOWSUWFHAWMC-SECBINFHSA-N n-[4-[(3r)-3-aminopyrrolidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound C=12C(NC(=O)C(C)C)=CNC2=NC=C(Br)C=1N1CC[C@@H](N)C1 HHWOWSUWFHAWMC-SECBINFHSA-N 0.000 description 1
- HHWOWSUWFHAWMC-VIFPVBQESA-N n-[4-[(3s)-3-aminopyrrolidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound C=12C(NC(=O)C(C)C)=CNC2=NC=C(Br)C=1N1CC[C@H](N)C1 HHWOWSUWFHAWMC-VIFPVBQESA-N 0.000 description 1
- HPBKTOHKWVMDLZ-GFCCVEGCSA-N n-[5-bromo-4-[(3r)-3-(ethylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound C1[C@H](NCC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C(C)C)=CN2 HPBKTOHKWVMDLZ-GFCCVEGCSA-N 0.000 description 1
- OIONZBAXXSNKIQ-GFCCVEGCSA-N n-[5-bromo-4-[(3r)-3-(ethylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1[C@H](NCC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1CC1)=CN2 OIONZBAXXSNKIQ-GFCCVEGCSA-N 0.000 description 1
- RTHXWEICSABYQR-LLVKDONJSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-1-methyl-6-oxopyridazine-3-carboxamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1=NN(C)C(=O)C=C1)=CN2 RTHXWEICSABYQR-LLVKDONJSA-N 0.000 description 1
- ZHUHFIKLEHDPGW-LLVKDONJSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-ethoxyacetamide Chemical compound C=12C(NC(=O)COCC)=CNC2=NC=C(Br)C=1N1CCC[C@@H](NC)C1 ZHUHFIKLEHDPGW-LLVKDONJSA-N 0.000 description 1
- AYGXAXKQGVXYEP-GFCCVEGCSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-propan-2-yloxyacetamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)COC(C)C)=CN2 AYGXAXKQGVXYEP-GFCCVEGCSA-N 0.000 description 1
- FXKUNOKYNGPUSU-ZGTCLIOFSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-propan-2-yloxypropanamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C(C)OC(C)C)=CN2 FXKUNOKYNGPUSU-ZGTCLIOFSA-N 0.000 description 1
- AENLUVVZDMVGIY-LLVKDONJSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]-3-methoxypropanamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)CCOC)=CN2 AENLUVVZDMVGIY-LLVKDONJSA-N 0.000 description 1
- WBYHZIFOGFDQFB-LLVKDONJSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrimidine-2-carboxamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C=1N=CC=CN=1)=CN2 WBYHZIFOGFDQFB-LLVKDONJSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5292608P | 2008-05-13 | 2008-05-13 | |
| US52926P | 2008-05-13 | ||
| PCT/US2009/043691 WO2009140320A1 (en) | 2008-05-13 | 2009-05-13 | Pyrrolopyridines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2552643T3 true ES2552643T3 (es) | 2015-12-01 |
Family
ID=40810786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09747404.3T Active ES2552643T3 (es) | 2008-05-13 | 2009-05-13 | Pirrolopiridinas como inhibidores de cinasa |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8178131B2 (https=) |
| EP (2) | EP2990407B1 (https=) |
| JP (2) | JP5703212B2 (https=) |
| KR (2) | KR101643426B1 (https=) |
| CN (3) | CN109942575A (https=) |
| AR (1) | AR071717A1 (https=) |
| AU (1) | AU2009246402B2 (https=) |
| BR (1) | BRPI0913580B8 (https=) |
| CA (1) | CA2724262C (https=) |
| CL (1) | CL2009001152A1 (https=) |
| CO (1) | CO6321244A2 (https=) |
| CR (1) | CR11803A (https=) |
| CY (1) | CY1116692T1 (https=) |
| DK (1) | DK2307409T3 (https=) |
| ES (1) | ES2552643T3 (https=) |
| HK (1) | HK1219950A1 (https=) |
| HR (1) | HRP20151018T1 (https=) |
| HU (1) | HUE026160T2 (https=) |
| IL (1) | IL209258A (https=) |
| MX (1) | MX2010012449A (https=) |
| NZ (1) | NZ589318A (https=) |
| PH (1) | PH12013501779B1 (https=) |
| PL (1) | PL2307409T3 (https=) |
| PT (1) | PT2307409E (https=) |
| RS (1) | RS54358B1 (https=) |
| RU (1) | RU2517194C2 (https=) |
| SI (1) | SI2307409T1 (https=) |
| TW (2) | TWI458727B (https=) |
| UA (1) | UA111933C2 (https=) |
| WO (1) | WO2009140320A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2711614A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| CA2711741A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| JP2009256298A (ja) * | 2008-03-26 | 2009-11-05 | Sumitomo Chemical Co Ltd | ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体 |
| CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| JP5805071B2 (ja) * | 2009-04-11 | 2015-11-04 | アレイ バイオファーマ、インコーポレイテッド | Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤 |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| KR101541086B1 (ko) | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| RU2017127088A (ru) * | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| BR112013021675A2 (pt) | 2011-02-25 | 2016-11-01 | Array Biopharma Inc | compostos de triazolopiridina como inibidores de pim cinase |
| CA2834166A1 (en) | 2011-04-29 | 2012-11-01 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| SG11201406818VA (en) | 2012-04-23 | 2014-11-27 | Genentech Inc | Intermediates and processes for preparing compounds |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
| CN105705499B (zh) * | 2013-08-22 | 2018-10-12 | 基因泰克公司 | 用于制备化合物的方法 |
| SG11201602265PA (en) * | 2013-09-25 | 2016-04-28 | Vertex Pharma | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| MA41599A (fr) | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
| WO2017003090A1 (ko) | 2015-06-30 | 2017-01-05 | 서울바이오시스 주식회사 | Uv led가 적용된 포충기 |
| PL3371165T3 (pl) * | 2015-11-04 | 2022-05-02 | Merck Patent Gmbh | Inhibitor btk do zastosowania w terapii rakowej |
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN120004785A (zh) * | 2018-07-03 | 2025-05-16 | 诺华制药股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| CN109053526A (zh) * | 2018-08-13 | 2018-12-21 | 南通大学 | 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法 |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| WO2022015975A1 (en) | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4274824A1 (en) | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| IL310724A (en) | 2021-08-10 | 2024-04-01 | Ifm Due Inc | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY |
| CN119798252A (zh) * | 2023-10-09 | 2025-04-11 | 中国石油化工股份有限公司 | 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法 |
| WO2025260014A1 (en) * | 2024-06-14 | 2025-12-18 | Tenvie Therapeutics, Inc. | Compounds, compositions, and methods |
| WO2025261366A1 (zh) * | 2024-06-18 | 2025-12-26 | 南京正大天晴制药有限公司 | 一种五元并六元杂环化合物及用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0723545B1 (en) * | 1993-10-14 | 2002-05-08 | Abbott Laboratories | Quinolizinone type compounds |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| MXPA02010222A (es) | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pirazoles para inhibir proteina cinasa. |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| AU2003250539A1 (en) | 2002-08-07 | 2004-02-25 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| TWI270549B (en) | 2002-12-26 | 2007-01-11 | Taisho Pharmaceutical Co Ltd | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
| EP1613625A1 (en) | 2003-03-14 | 2006-01-11 | AstraZeneca AB | Novel fused triazolones and the uses thereof |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| AR049333A1 (es) * | 2004-04-02 | 2006-07-19 | Vertex Pharma | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. |
| TWI380816B (zh) * | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
| JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1869052A1 (en) | 2005-04-06 | 2007-12-26 | AstraZeneca AB | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| CA2621181C (en) * | 2005-08-30 | 2011-04-19 | Asahi Kasei Pharma Corporation | 5-isoquinolinesulfonamide compounds |
| JP5052518B2 (ja) | 2005-10-06 | 2012-10-17 | シェーリング コーポレイション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
| DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
| DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| US8618121B2 (en) * | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| JP2011503084A (ja) | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| CA2711614A1 (en) * | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| CA2711741A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US20140221370A1 (en) | 2010-07-09 | 2014-08-07 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| RU2017127088A (ru) | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
-
2009
- 2009-05-12 CL CL2009001152A patent/CL2009001152A1/es unknown
- 2009-05-12 AR ARP090101708A patent/AR071717A1/es active IP Right Grant
- 2009-05-13 RS RS20150711A patent/RS54358B1/sr unknown
- 2009-05-13 CA CA2724262A patent/CA2724262C/en active Active
- 2009-05-13 JP JP2011509628A patent/JP5703212B2/ja not_active Expired - Fee Related
- 2009-05-13 US US12/992,468 patent/US8178131B2/en active Active
- 2009-05-13 CN CN201910068067.1A patent/CN109942575A/zh active Pending
- 2009-05-13 SI SI200931284T patent/SI2307409T1/sl unknown
- 2009-05-13 ES ES09747404.3T patent/ES2552643T3/es active Active
- 2009-05-13 MX MX2010012449A patent/MX2010012449A/es active IP Right Grant
- 2009-05-13 CN CN200980127299.4A patent/CN102089307B/zh not_active Expired - Fee Related
- 2009-05-13 TW TW098115906A patent/TWI458727B/zh not_active IP Right Cessation
- 2009-05-13 RU RU2010150786/04A patent/RU2517194C2/ru active
- 2009-05-13 CN CN201510289964.7A patent/CN104926810B/zh not_active Expired - Fee Related
- 2009-05-13 WO PCT/US2009/043691 patent/WO2009140320A1/en not_active Ceased
- 2009-05-13 KR KR1020107027941A patent/KR101643426B1/ko not_active Expired - Fee Related
- 2009-05-13 PT PT97474043T patent/PT2307409E/pt unknown
- 2009-05-13 PL PL09747404T patent/PL2307409T3/pl unknown
- 2009-05-13 HU HUE09747404A patent/HUE026160T2/en unknown
- 2009-05-13 HR HRP20151018TT patent/HRP20151018T1/hr unknown
- 2009-05-13 KR KR1020147015705A patent/KR101657856B1/ko not_active Expired - Fee Related
- 2009-05-13 EP EP15175131.0A patent/EP2990407B1/en active Active
- 2009-05-13 BR BRPI0913580A patent/BRPI0913580B8/pt not_active IP Right Cessation
- 2009-05-13 EP EP09747404.3A patent/EP2307409B1/en active Active
- 2009-05-13 AU AU2009246402A patent/AU2009246402B2/en not_active Ceased
- 2009-05-13 UA UAA201015012A patent/UA111933C2/uk unknown
- 2009-05-13 TW TW103133772A patent/TWI554512B/zh not_active IP Right Cessation
- 2009-05-13 DK DK09747404.3T patent/DK2307409T3/en active
- 2009-05-13 NZ NZ589318A patent/NZ589318A/en not_active IP Right Cessation
-
2010
- 2010-11-11 IL IL209258A patent/IL209258A/en active IP Right Grant
- 2010-11-19 CR CR11803A patent/CR11803A/es unknown
- 2010-11-30 CO CO10150963A patent/CO6321244A2/es active IP Right Grant
-
2012
- 2012-03-20 US US13/425,186 patent/US8545897B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 US US13/974,895 patent/US8758830B2/en active Active
- 2013-08-28 PH PH12013501779A patent/PH12013501779B1/en unknown
-
2014
- 2014-05-06 US US14/271,129 patent/US8981085B2/en active Active
-
2015
- 2015-01-07 US US14/591,691 patent/US9365568B2/en active Active
- 2015-02-23 JP JP2015032474A patent/JP2015098482A/ja not_active Withdrawn
- 2015-09-16 CY CY20151100812T patent/CY1116692T1/el unknown
-
2016
- 2016-01-05 US US14/988,521 patent/US9969727B2/en active Active
- 2016-07-08 HK HK16107983.6A patent/HK1219950A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2552643T3 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AU2021245168B2 (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| CN114845711B (zh) | Raf激酶的抑制剂 | |
| DK2444395T3 (en) | substituted isoquinoline | |
| CN118900838A (zh) | 杂环化合物、其组合物及其治疗方法 | |
| JP7774709B2 (ja) | インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用 | |
| JP2019519585A (ja) | Ｈｂｖ感染の処置および予防のための新規のテトラヒドロピリドピリミジン | |
| AU2021277619B2 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors | |
| TWI749644B (zh) | 一種氰基取代的環肼衍生物及其應用 | |
| AU2015291478B2 (en) | Novel substituted pyrimidine compounds | |
| EA031905B1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| AU2017287762A1 (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| JP2021529815A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 | |
| EP3844159B1 (en) | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease | |
| WO2020048605A1 (en) | Novel pyrrolidine amine compounds for the treatment of autoimmune disease | |
| CA2952339A1 (en) | 3-substituted 2-amino-indole derivatives | |
| EA037520B1 (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2 | |
| KR102666918B1 (ko) | 신규한 lrrk2 억제제 | |
| JP7349570B2 (ja) | Ｍ４作動薬としての２－アザスピロ［３．４］オクタン誘導体 | |
| CA3249080A1 (en) | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT | |
| AU2022390051A1 (en) | Heterocyclic amides and methods of using the same | |
| AU2020421654A1 (en) | RORγt inhibitor, preparation method thereof and use thereof | |
| WO2025111408A1 (en) | Compounds for treating spinal muscular atrophy and huntington's disease | |
| EP4584273A1 (en) | Lrrk2 inhibitors and uses thereof | |
| AU2019361539B2 (en) | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof |